A prior infection with SARS-CoV-2, the virus that causes COVID-19, appears to protect, at least for a few months, against reinfection from the virus, according to an NCI study. The finding may have important public health implications.
For patients with cancers that do not respond to immunotherapy drugs, the use of fecal transplants to modify the gut microbiome may help some of these patients respond to the immunotherapy drugs.
Some postmenopausal women with HR-positive, HER2-negative breast cancer may not benefit from chemotherapy and can safely forgo the treatment, according to clinical trial results presented at the San Antonio Breast Cancer Symposium.
A comprehensive analysis of patients with cancer who had exceptional responses to therapy has revealed molecular changes in the patients’ tumors that may explain some of the exceptional responses.
NCI and the National Institute of Biomedical Imaging and Bioengineering have awarded seven contracts to develop digital health solutions, like smartphone apps, wearable devices, and software, that help address the COVID-19 pandemic.
NCI and Cancer Research UK will partner to fund Cancer Grand Challenges, an international initiative to address profound and unanswered questions in cancer research.
Mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment, an NCI study shows.
In a new study, an automated dual-stain method using artificial intelligence improved the accuracy and efficiency of cervical cancer screening compared with the current standard for follow-up of women who test positive with primary HPV screening.
The new test is relatively simple and could improve screening for people who are at risk for developing hepatocellular carcinoma (HCC), the most common form of liver cancer. It could help doctors find and treat HCC early.
As described in an NCI Media Availability, early data from a clinical study suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.